of 1 /1
NEW PATENTS This Section contains abstracts (without graphics) of recently issued United States patents and published patent applications filed from over 30 countries under the Patent Cooperation Treaty. This information was obtained from recent additions to the Pergamon PATSEARCH x online database in accordance with interest profiles developed by the Editors. Further information about Pergamon PATSEARCH~ can be obtained from Pergamon InfoLine Inc., 1340 Old Chain Bridge Road, McLean, Virginia 22101 U:S.A. Copies of complete patents announced in this Section are available from Pergamon lnfoLine inc. for $8 per copy. Payment with order is required. Orders outside North America add $2 for air postage. Order by patent number for Pergamon InfoLine only. Mutation/Genetic Engineering Techniques 4613~2 YEAST BARI GENE PLASMID Vivian L MacKay, Thomas R Manney assigned to Kansas State University Research Founda- tion; Rutgers Research and Educational Foun- dati The yeast BAR 1 structural gene is disclosed. The gene was cloned in E. coli and expressed in two different yeasts, Saccharomyces and Schizosac- charomyces. 4616099 FAMILY GROUP OF SUCCESSIVE RADIATION INDUCED CHRYSANTHEMUM MUTANTS NAMED SNAPPER A Graham Sparkes, Ferring, Worthing, West Sussex, United Kingdom This invention comprises a family of distinctive chrysanthemum morifolium cultivars orig- inating from a selected seedling of a genotype produced by cross-breeding and developed from the genotype by irradiation of selected clones of successive mutants induced by radiation. 4616078 PROCESS FOR PURIFYING PROINSULIN-LIKE MATERIALS Richard D DiMarchi assigned to Eli Lilly and Company This specification describes a process for separating impurities from an impure mixture containing proinsulin-like material with sub- stantially complete recovery of said proinsulin- like material, which comprises: (I) applying said mixture to a reverse phase macroporous acrylate ester copolymer resin support at a pH of from about 7 to about 10; and (2) eluting said proinsulin-like material from said support with an aqueous ¢luant having a pH of from about 8 to about I I and containing from about 10% to about 30% by volume of an organic diluent selec- ted from the group consisting of acetone, ac- etonitrile, and a combination of acetone and acetonitrile. 462~19 METHOD FOR THE DETERMINATION OF LIABILITY IN HUMAN INDIVIDUALS TO DEVELOP ATHEROSCLEROSIS David Owerbach, Jorn Nerup, Gentofte, Den- mark assigned to Nordisk lnsulinlaboratorium Liability in human individuals to develop non- insulin-dependent diabetes mellitus (N1DDM) and/or atberosclcrosis is determined by restric- tion enzyme mapping of DNA from a human in- dividual using a probe selected from the group consisting of (i) eDNA complementary to the mRNA coding for the human insulin, (ii) human genomic DNA containing the actual insulin gene, (iii) DNA sequences of human genomic DNA located within 20"106 base pairs from the insulin gone in either direction, and examining the distribution of DNA fragments for the ap- pearance of insertion sequences of approx- imately 1600 to 2300 base pairs (U alleles) the 147

4616078 Process for purifying proinsulin-like materials

Embed Size (px)

Citation preview

NEW PATENTS

This Section contains abstracts (without graphics) of recently issued United States patents and published patent applications filed from over 30 countries under the Patent Cooperation Treaty. This information was obtained from recent additions to the Pergamon PATSEARCH x online database in accordance with interest profiles developed by the Editors. Further information about Pergamon PATSEARCH ~ can be obtained from Pergamon InfoLine Inc., 1340 Old Chain Bridge Road, McLean, Virginia 22101 U:S.A.

Copies of complete patents announced in this Section are available from Pergamon lnfoLine inc. for $8 per copy. Payment with order is required. Orders outside North America add $2 for air postage. Order by patent number for Pergamon InfoLine only.

Mutation/Genetic Engineering Techniques

4 6 1 3 ~ 2

YEAST BARI GENE PLASMID

Vivian L MacKay, Thomas R Manney assigned to Kansas State University Research Founda- tion; Rutgers Research and Educational Foun- dati

The yeast BAR 1 structural gene is disclosed. The gene was cloned in E. coli and expressed in two different yeasts, Saccharomyces and Schizosac- charomyces.

4616099

FAMILY GROUP OF SUCCESSIVE RADIATION INDUCED

CHRYSANTHEMUM MUTANTS NAMED SNAPPER

A Graham Sparkes, Ferring, Worthing, West Sussex, United Kingdom

This invention comprises a family of distinctive chrysanthemum morifolium cultivars orig- inating from a selected seedling of a genotype produced by cross-breeding and developed from the genotype by irradiation of selected clones of successive mutants induced by radiation.

4616078

PROCESS FOR PURIFYING PROINSULIN-LIKE MATERIALS

Richard D DiMarchi assigned to Eli Lilly and Company

This specification describes a process for separating impurities from an impure mixture containing proinsulin-like material with sub- stantially complete recovery of said proinsulin- like material, which comprises: (I) applying said mixture to a reverse phase macroporous acrylate ester copolymer resin support at a pH of from about 7 to about 10; and (2) eluting said proinsulin-like material from said support with an aqueous ¢luant having a pH of from about 8 to about I I and containing from about 10% to about 30% by volume of an organic diluent selec- ted from the group consisting of acetone, ac- etonitrile, and a combination of acetone and acetonitrile.

4 6 2 ~ 1 9

METHOD FOR THE DETERMINATION OF LIABILITY

IN HUMAN INDIVIDUALS TO DEVELOP ATHEROSCLEROSIS

David Owerbach, Jorn Nerup, Gentofte, Den- mark assigned to Nordisk lnsulinlaboratorium

Liability in human individuals to develop non- insulin-dependent diabetes mellitus (N1DDM) and/or atberosclcrosis is determined by restric- tion enzyme mapping of DNA from a human in- dividual using a probe selected from the group consisting of (i) eDNA complementary to the mRNA coding for the human insulin, (ii) human genomic DNA containing the actual insulin gene, (iii) DNA sequences of human genomic DNA located within 20"106 base pairs from the insulin gone in either direction, and examining the distribution of DNA fragments for the ap- pearance of insertion sequences of approx- imately 1600 to 2300 base pairs (U alleles) the

147